Comparative Pharmacology
Head-to-head clinical analysis: INVAGESIC versus INVAGESIC FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVAGESIC versus INVAGESIC FORTE.
INVAGESIC vs INVAGESIC FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INVAGESIC is a combination of pregabalin, an alpha2-delta ligand that inhibits presynaptic calcium channels to reduce excitatory neurotransmitter release, and meloxicam, a COX-2 selective NSAID that decreases prostaglandin synthesis via cyclooxygenase inhibition.
Combination of an opioid agonist (codeine) and a non-opioid analgesic (ibuprofen). Codeine is metabolized to morphine, which binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Ibuprofen inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Adults: 1-2 tablets (325 mg acetaminophen/5 mg hydrocodone) orally every 4-6 hours as needed for pain, not to exceed 12 tablets per day.
One tablet (hydrocodone bitartrate 10 mg / acetaminophen 300 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; prolonged to 8-12 hours in elderly or mild renal impairment
Terminal half-life: 2-3 hours (prolonged in renal impairment; clinical context: requires dosing interval adjustment in CrCl <30 mL/min)
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites
Renal: 90% (70% unchanged, 20% as glucuronide conjugate); Fecal/biliary: <5%
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination